
Going Faster with LEN Generics

AVAC
Advocacy. Access. Equity.
Nov 2026 | avac.org

LEN generics submitted for regulatory approval ahead of CAB generics, primarily because LEN was licensed even before regulatory submission and approval and because BE timelines were shorter for LEN than for CAB.



This graphic aims to exhibit average timelines, but it is important to acknowledge that each generic manufacturer will move at different timelines and that unanticipated delays can happen at any step of the processes shown above. This graphic therefore aims to estimate timelines but should be used as a guideline rather than taken as 100% definitive.